← Back to Search

Other

ALTO-100 PO Tablet for Depression

Phase 2
Waitlist Available
Research Sponsored by Alto Neuroscience
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Willing to comply with all study assessments and procedures
Have a diagnosis of moderate to severe major depressive disorder
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured at day 1, day 14, day 28, day 42, day 56
Awards & highlights

Study Summary

This trial will help researchers understand how safe and effective ALTO-100 is for people with Alzheimer's disease.

Eligible Conditions
  • Depression

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured at day 1, day 14, day 28, day 42, day 56
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured at day 1, day 14, day 28, day 42, day 56 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Clinically Significant Laboratory Abnormalities as a Measure of Safety and Tolerability of ALTO-100
Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability of ALTO-100
To understand the relationship between baseline biology and score change in the Clinical Global Impression scale - Severity (CGI-S) with ALTO-100 from Screening to end of treatment
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: ALTO-100Experimental Treatment1 Intervention
ALTO-100 tablet PO ; twice daily dosing 8 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ALTO-100 PO Tablet
2022
Completed Phase 2
~30

Find a Location

Who is running the clinical trial?

Alto NeuroscienceLead Sponsor
7 Previous Clinical Trials
950 Total Patients Enrolled
7 Trials studying Depression
950 Patients Enrolled for Depression

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the age limit for enrollment into this clinical trial greater than 65?

"This medical research is open to applicants aged 18 years or older and younger than 65."

Answered by AI

What is the eligibility criteria for participants in this research?

"This medical trial requires individuals suffering from major depressive disorder to be admitted, with the age requirement being between 18 and 64. The number of participants needed for this experiment is approximately 50."

Answered by AI

How reliable is ALTO-100 PO Tablet in terms of patient safety?

"Based on prior clinical data, ALTO-100 PO Tablet's safety has been evaluated as a 2. As this is only a phase two trial, there are some indications of safety but no evidence yet for efficacy."

Answered by AI

Is this research recruitment still open?

"This medical experiment is not currently recruiting, after being first posted on June 1st 2022 and its most recent update occuring October 21st 2022. Nevertheless, there are presently 1295 other trials actively seeking participants."

Answered by AI

Who else is applying?

What site did they apply to?
Site 156
What portion of applicants met pre-screening criteria?
Met criteria

Why did patients apply to this trial?

I want to be happy again.
PatientReceived 2+ prior treatments
~8 spots leftby Mar 2025